- 1 **Title:** Changes in life expectancy and life span equality during the COVID-19 epidemic
- 2 in Japan up to 2022.
- **3 Running title:** Demographic impact of COVID-19 pandemic in Japan
- 4 Article type: Original Article
- 5
- 6 Authors:
- 7 Yuta Okada^a, Hiroshi Nishiura^a
- ^a Graduate School of Medicine, Kyoto University, Kyoto 6068503, Japan
- 9
- 10 Correspondence to: Hiroshi Nishiura
- 11 Address: Kyoto University, Yoshidakonoecho, Sakyoku, Kyoto city, Kyoto 6068503,
- 12 Japan
- 13 Tel: +81-75-753-4456; Fax: +81-75-753-4458
- 14 Email: nishiura.hiroshi.5r@kyoto-u.ac.jp
- 15
- 16

17 Abstract

- 18 **Objectives:** To evaluate the impact of COVID-19 on life expectancy in Japan through
- 19 demographic analyses.
- 20 Methods: We evaluated the relationship between the life expectancy gap from 2020–21
- and 2021–22 and COVID-19 epidemic size at prefectural level. We also conducted age-
- 22 and cause-specific decomposition of life expectancy change. Trends in life span equality
- from 2000–22 were evaluated at the national level.
- 24 **Results**: Prefectural analysis of 2021–22 life expectancy change and annual per-
- 25 population COVID-19 cases, person-days in intensive care, and reported COVID-19
- 26 deaths showed no significant correlations, unlike our analysis from 2020–21. However,
- 27 decomposition analysis revealed substantial life expectancy shortening attributable to
- the population over 35 years old. It also showed large increases in causes of death such
- as cardiovascular or respiratory disorders as well as COVID-19. Whole-population life
- 30 span equality declined in 2020 but increased in 2021 and 2022 despite the shorter life
- 31 expectancy.
- 32 Conclusions: Discrepancy between life expectancy change and COVID-19 statistics in
 33 2022 suggests the growing ascertainment bias of COVID-19. The increased contribution
 34 of cardiovascular disorders to life expectancy shortening is an alarming sign for the

- 35 future. Life span equality changes in 2021 and 2022 can probably be attributed to
- 36 increased mortality among older people.
- 37
- 38 Keywords: COVID-19; life expectancy; Arriaga Method; life span equality; Japan
- 39

```
40 Highlights
```

41	•	Life expectancy change was not correlated with COVID-19 epidemic activity in 2022
42	•	Older people made the biggest contribution to shorter life expectancy
43	•	Cardiovascular disorders contributed substantially to shortening of life expectancy
44	•	Life span equality increased in 2021 and 2022 despite shorter life expectancy

45 Introduction

46	Since the start of the COVID-19 pandemic in Wuhan, China in November 2019,
47	evidence of the pandemic's impact on mortality has accumulated globally, with
48	substantial geographical heterogeneity. [1–6] Global studies suggest that from January
49	1 st , 2020 to December 31 st , 2021, excess deaths worldwide were in the range of 14.9–
50	15.9 million, with a large proportion attributed to India and the United States. [3,4]
51	Published studies suggest that the global life expectancy change was -1.6 years from

52	2019 to 2021, when many countries showed bounce-backs from the shortening in 2020.
53	However, other countries faced sustained shortening into 2021. [4-6]
54	It is now several years since the emergence of COVID-19, and the evaluation of the
55	mortality impact of the condition has become more difficult for several reasons. One
56	reason is changes in the official COVID-19 statistics, which are provided by public
57	health agencies around the world and reflect epidemic activity. These are now less
58	rigorous than in 2020, because most countries have gradually diminished their effort
59	either to control the spread of COVID-19 or to maintain a meticulous surveillance
60	system. Another reason is the change in the nature of deaths associated with COVID-19
61	since the introduction of vaccines against the disease in late 2020. The direct mortality
62	impact of COVID-19 has been alleviated by these vaccines, but a substantial proportion
63	of deaths are caused indirectly through complications such as cardiovascular disorders,
64	or by limited access to healthcare services when the healthcare capacity or ambulance
65	system were overwhelmed by the increased case load pressure of COVID-19.[5,7-15]
66	The ongoing emergence of SARS-CoV-2 variants with a high capability of immune
67	evasion and transmission may have worsened the health impact of COVID-19, but
68	understanding the true burden has remained a challenging task.[16,17]

69	Direct approaches to estimating the mortality impact of COVID-19 are therefore
70	challenging, including in Japan. There, the epidemic size of COVID-19 was greatest
71	upon the emergence of SARS-CoV-2 Omicron (B.1.1.529) lineage variants. In line with
72	other regions, Japan has been severely affected by COVID-19 in terms of excess
73	mortality and life expectancy shortening. [1,3–5,14,18–21] The updated estimates by
74	the National Institute of Population and Social Security Research suggest that life
75	expectancy at birth has shortened for two consecutive years, from 84.58 years in 2021
76	to 84.10 in 2022 for the total population. However, it is not clear whether the cause-
77	specific impact of this shortening has changed since 2021. It is also not clear how the
78	contribution of cardiovascular, respiratory, and neoplastic disorders in 2021 have
79	changed.[18] From a demographic perspective, the change in life span equality during
80	and since the COVID-19 pandemic is also interesting. One measure of life span equality,
81	or, evenness of life span, is the logarithm of the inverse of life table entropy. Global and
82	historical demographic analysis suggests that the trends in life expectancy at birth and
83	life span equality have been in line with each other. [22,23] However, this might not be
84	the case when the age-mortality structure changes drastically. For example, during the
85	COVID-19 epidemic in Japan, the mortality increase in 2021 contributed substantially
86	to shorter life expectancy. [18]

87	To examine the demographic impact of the COVID-19 epidemic in 2022 in Japan, we
88	investigated the relationship between reported COVID-19 burden at the prefectural level
89	and life expectancy. We also decomposed the year-on-year life expectancy change from
90	2019–22 by age groups and major causes of death, and evaluated the lifetime loss by
91	age and life span equality during the COVID-19 epidemic.

92 Methods

93 Epidemiological data

94	We used the data on deaths and exposure-to-risk populations available in the
95	Japanese Mortality Database (JMD), which was available for the whole of Japan and by
96	prefecture.[24] Death counts by cause of death and age group were obtained from the
97	vital statistics published by the Ministry of Health, Labour and Welfare of Japan.[24] In
98	line with a previous study, we categorized major causes of death using the International
99	Statistical Classification of Diseases and Related Health Problems 10 th Revision (ICD-
100	10) into the top nine major cause categories (based on death counts by cause in 2022),
101	and aggregated the remainder into a single group, to give a total of ten groups.[18] The
102	epidemiological data for COVID-19 were retrieved from the open-access data provided
103	by the Ministry of Health, Labour and Welfare. [24]

104 Calculation of period life table

- 105 For subsequent use for age- and cause-specific decomposition of life expectancy
- 106 gaps, we re-calculated period life tables from 2000 to 2022 for the whole of Japan and
- 107 for all prefectures as described before. [18,24] We obtained age group-specific mortality
- 108 m_x using death counts and exposure-to-risk population in each age group x. Using m_x
- 109 and a_x , the average length of time to death in deceased individuals in age group x, we
- 110 calculated q_x , the probability of death in age group x as:

$$q_x = \begin{cases} \frac{m_x w_x}{1 + (w_x - a_x) m_x}, & x = 0, 1 - 4, 5 - 9, \dots 95 - 99, \\ 1, & x = 100 +, \end{cases}$$

111 where w_x is the time interval of age group x. Starting from an initial population

$$l_0 = 100,000,$$

112 l_x can be obtained by iteratively applying the formula:

$$l_{x+1} = l_x (1 - q_x),$$

113 for age groups $x = 0, 1-4, 5-9, \dots 100 + (\text{in years})$. Using l_x and a_x values,

$$L_{x} = w_{x}l_{x+1} + a_{x}d_{x} = w_{x}l_{x+1} + a_{x}l_{x}q_{x},$$
$$T_{x} = \sum_{i=x}^{100+} L_{i},$$

114 where L_x is the person-years spent in age group x, $d_x = l_x q_x$ is the number of deaths in

- 115 age group x, and T_x is the person-years of life remaining for those in age group x. The
- 116 life expectancy of age group x, e_x , is then calculated as:

$$e_x = \frac{T_x}{l_x},$$

117 and the life expectancy at birth is calculated as $e_0 = T_0/l_0$.

118 Life expectancy change and COVID-19 statistics at the prefectural level

- 119 Three COVID-19 statistics at prefectural level were used for this analysis: (i)
- 120 annual number of COVID-19 cases, (ii) annual number of person-days in intensive care
- 121 because of COVID-19, and (iii) annual number of documented deaths due to COVID-19.
- 122 Using each of the COVID-19 indicators as an explanatory variable, we used linear
- 123 regression analysis to predict the year-on-year life expectancy change as the dependent
- 124 variable for 2020–21 and 2021–22.

125 Decomposition of annual life expectancy change by age and cause of death

126 In line with a recent study, we used the Arriaga method for age- and cause-

127 specific decomposition of life expectancy change. [18,25] The total contribution of age

128 group x to the life expectancy change (in years), denoted as C_x , can be described as:

129
$$C_{x} = \left[\frac{l_{x}^{2020}}{l_{0}} \left(\frac{L_{x}^{2021}}{l_{x}^{2021}} - \frac{L_{x}^{2020}}{l_{x}^{2020}}\right)\right] + \left[\frac{T_{x+1}^{2021}}{l_{0}} \left(\frac{l_{x}^{2020}}{l_{x}^{2021}} - \frac{l_{x+1}^{2020}}{l_{x+1}^{2021}}\right)\right].$$
(1)

130 We then decomposed C_x into cause-specific contributions:

131
$$C_x^i = C_x \left[\frac{R_x^{i,2021} m_x^{2021} - R_x^{i,2020} m_x^{2020}}{m_x^{2021} - m_x^{2020}} \right], \tag{2}$$

132 where C_x^i is the contribution of cause of death *i* in age group $x_i R_x^i$ is the proportion of

133 deaths in age group x associated with cause i, and m_x is the overall mortality rate in age

134 group *x*.

135 Life span equality h

136 We used a measure of life span equality h, which was derived from life table

137 entropy \overline{H} . [22,26,27] Life table entropy $\overline{H}(t)$ is a measure of variation, or inequality, in

138 life span at time *t* that is defined as:

$$\overline{H}(t) = -\frac{\int_0^\infty l(x,t) \ln(l(x,t)) dx}{\int_0^\infty l(x,t) dx} = \frac{e^+(0,t)}{e_0(t)},$$

139 where $e^{\dagger}(0, t)$ is the special case of:

$$e^{\dagger}(x,t) = -\frac{\int_{x}^{\infty} l(a,t) \ln(l(a,t)) da}{l(x,t)} = \frac{\int_{x}^{\infty} d(x,t) e(x,t) dx}{l(x,t)},$$

140 which is the life disparity, or the life expectancy loss after birth, and e_0 is the life

141 expectancy at birth. Using $\overline{H}(t)$, life span equality h(t) is defined as:

$$h(t) = -\log(\overline{H}(t)).$$

142 Note that, contrary to
$$\overline{H}(t)$$
, the value of $h(t)$ is the measure of life span equality. We
143 used a 1×1 year life table provided by JMD to calculate $h(t)$ from 2000 to 2022 for
144 total, male, and female populations, and evaluated the relationship between $h(t)$ and
145 life expectancy at birth, $e_0(t)$, for each of these populations. [28]

146 Aburto et al. [22] described the variation of h(t) over time as:

$$\frac{\partial h}{\partial t} = -\frac{\frac{\partial H}{\partial t}}{\overline{H}} = \int_0^\infty w(x,t) W_h(x,t) \rho(x,t) dx,$$

147 where

110

$$\rho(x,t) = -\frac{\frac{\partial \mu(x,t)}{\partial t}}{\mu(x,t)} = -\frac{\partial}{\partial t} \log(\mu(x,t))$$

148 is the mortality improvement in age x over time,

$$w(x,t) = \mu(x,t)l(x,t)e(x,t) = d(x,t)e(x,t)$$

149 is the weight of the contribution of $\rho(x, t)$ to life expectancy change in age x, and

$$W_h(x,t) = \frac{1}{e_0} - \frac{1}{e^{\dagger}} (H(x,t) + \overline{H}(x,t) - 1) = \frac{1}{e_0} - \frac{1}{e^{\dagger}} \left(\int_0^x \mu(x,t) dx + \frac{e^{\dagger}(x,t)}{e(x,t)} - 1 \right).$$

150 Thus, $w(x, t)W_h(x, t)$ can be considered as the weight, or sensitivity, of h(t) to $\rho(x, t)$

- at age x. We calculated $w(x, t)W_h(x, t)$ and the threshold age a^H that satisfies 151
- $W_h(a^H, t) = 0$ for $t = 2000, 2001, \dots, 2022$. These results were compared with year-152

153 on-year mortality improvement, i.e.,
$$r(x,t) = \log(\mu(a,t)) - \log(\mu(a,t+1))$$
, which

- 154 is analogous to $\rho(x, t)$ as described above. We calculated the values such as h(t), $\overline{H}(t)$,
- 155 and a^{H} in a discretized manner regarding ages, which has been previously described
- 156 elsewhere.[22,27]

157 Software

- 158 All analyses used R version 4.2.2. [29]
- 159 Results
- 160 The life expectancy at birth in Japan for the total, male, and female populations
- 161 from 2019–2022 is shown in Supplementary Table 1. These results were based on
- abridged life tables that we re-calculated for use in Arriaga decomposition, but which
- are almost identical to results provided by JMD. The life expectancy of the total
- population decreased by 0.49 years, from 84.59 to 84.10 from 2021–22. A decrease in
- life expectancy was also seen from 2020–21 of 0.15 years (from 84.74 to 84.59 years).
- 166 However, the magnitude of the shortening was greater in 2021–22. The shortening of
- 167 life expectancy at birth for both male and female populations also increased from 2021–
- 168 22, by 0.43 years for men (from 81.49 to 81.06 years) and 0.50 years for women (from
- 169 87.62 to 87.12 years).

170	Figure 1 shows life expectancy changes in the total population by prefecture in
171	2019–20, 2020–21, and 2021–22. Following the drastic change from an overall
172	increasing trend in 2019–20 to a sharply decreasing trend in 2020–21, all but one
173	prefecture saw a decline in life expectancy from 2021–22. In 2022, the greatest decrease
174	in life expectancy was seen in Iwate (1.00 years), and the only prefecture where life
175	expectancy continued to increase was Nagasaki (0.05 years). The prefecture-level life
176	expectancy changes of the male and female populations were largely consistent with
177	that for the total population (for the details, see Supplementary Data).
178	Figure 2 shows the correlation between reported COVID-19 burden and life
179	expectancy changes at the prefectural level. Combined with the linear regression results
180	shown in Table 1, there was no obvious correlation between annual reported cases,
181	person-days in intensive care, and death due to COVID-19 in 2021-22. However, this
182	was contrary to the findings from 2020–21.
183	Figure 3 shows the results of the Arriaga decomposition of life expectancy
184	change by age groups and major causes of death. An aggregated summary by age
185	groups and causes of death is shown in Supplementary Figures 1 and 2. There was a
186	clear negative contribution among the older population in 2020–21, and this negative

187	contribution was even bigger in 2021–22. The age range of the group contributing to the
188	reduction also widened in 2021–22 to as low as 30–34 years.
189	Figure 3 also shows the contributions of major causes of death by age groups.
190	The negative contribution of COVID-19 among the older population expanded
191	substantially in 2021–22. The total contribution by all ages grew from -0.095 years in
192	2020–21 to -0.131 years in 2021–22. In addition to COVID-19, the negative
193	contribution of cardiovascular causes also grew considerably in 2021–22, especially
194	among those over 50 years old. The total contribution of cardiovascular death was
195	-0.091 years in 2022, which was a consistent and substantial reduction compared with
196	+0.073 years in 2020 and -0.003 years in 2021. The negative contribution of "other"
197	causes (the remaining causes of death beyond the top nine major categories) also
198	increased substantially in 2021–22 among the population over 50 years old, with a total
199	of -0.139 years across all age groups. There was a clear decrease in the contribution of
200	respiratory and neoplastic disorders, and other causes from 2020-21 to 2021-22 (see
201	Supplementary Data for detailed results). Results from the decomposition analysis for
202	the male and female populations were similar to that of the total population
203	(Supplementary Data and Supplementary Figures 3 and 4).

204	The values of $h(t)$ as an indicator of life span equality for the total population
205	from 2000 to 2022 are shown in Figure 4. Panel (A) shows that h largely increased
206	consistently up to 2019, except in 2011 when an exceptional number of casualties
207	occurred due to the earthquake and tsunami that hit eastern Japan. That increasing trend
208	was halted in 2020 when the COVID-19 pandemic started, but has resumed since 2021.
209	The values of $h(t)$ for the female and male populations showed very similar patterns to
210	those for the total population (Supplementary Figures 5 and 6). Panel (B) in Figure 4
211	shows the relationship between $h(t)$ and life expectancy at birth from 2000 to 2022. A
212	decrease in $h(t)$ was seen in 2020 for the first time since 2011, and was followed by an
213	increase in 2021 and 2022 despite the shortening of life expectancy at birth.
214	To see how the overall dynamics of $h(t)$ from 2020 to 2022 can be explained
215	by mortality improvements by age for this period (in relation to a^H), we calculated
216	curves of $w(x, t)W_h(x, t)$ across ages for 2021 and 2022. We also evaluated the year-
217	on-year mortality improvement $r(x, t)$ from 2020 to 2022 for the total population
218	(Supplementary Figure 6). The curves of $w(x, t)W_h(x, t)$ for 2021 and 2022 were very
219	similar, although there was a slight shift toward the younger ages in the negative part of
220	the curve for the older population. As for $r(x, t)$, $r(x, 2020)$ above $x = a^H$ lay in the
221	positive range, whereas $r(x, 2021)$ and $r(x, 2022)$ mostly lay in the negative range for

222	the age range. For ages younger than $x = a^{H}$, the signs of $r(x, 2020)$, $r(x, 2021)$, and
223	r(x, 2022) were inconsistent across different ages, suggesting that increased mortality
224	among those older than a^{H} clearly contributed to the increase of $h(t)$ in 2021 and 2022
225	(see Supplementary Figures 7 and 8 for results on the female and male populations).

226 Discussion

227	Our study showed the	pattern of deaths in Jap	ban during the COVID-19

228 epidemic (up to 2022) through demographic information. The main finding was the

growing impact of the older population and cardiovascular deaths on the shortening of

230 life expectancy, which was considerable from 2021 to 2022. The lack of significant

231 correlations between life expectancy change and epidemiological indicators of the

232 COVID-19 burden from 2022 is also a concern. This finding may be linked to the low

detection of COVID-19 cases and associated deaths, which is supported by our results

about the age- and cause-specific contributions to life expectancy change. The

increasing trend in life span equality despite the life expectancy shortening may also be

related to the substantial increase in mortality among the older population.

- 237 There were two key findings from our study. The first was that all age groups
- 238 over 30 years old contributed to the shortening of life expectancy in 2022, as shown in

239	Figure 3 and Supplementary Figure 1. However, compared with the overall shortening
240	attributed to age groups over 50 in 2021, the negative impact was more diffuse across
241	ages. This finding is similar to what was observed in 2020-21 in countries in Eastern
242	Europe, though the underlying situations in these countries, such as types of circulating
243	SARS-CoV-2 variants, vaccine coverage, and healthcare situations, would have been
244	quite different from that in Japan from 2021–22. [5] In Japan, the population-wide
245	vaccine coverage of the second dose of mRNA vaccines (BNT162b2 [Pfizer/BioNTech]
246	and mRNA-1273 [Moderna] vaccines) was around 80% by the end of 2021, and the
247	coverage of the third dose also increased from around 15% at the end of 2021 to 68% by
248	the end of 2022. [24] Despite this high vaccination rate, we found substantial mortality
249	caused by COVID-19 in Japan among wider age groups in 2022. This was not fully
250	captured by COVID-19 statistics, as seen in our prefectural analyses (Figure 2 and
251	Table 1).
252	Another key finding was the substantial growth in the negative contribution of
253	cardiovascular disorders to life expectancy shortening, especially among populations
254	over 50 years old (Figure 3 and Supplementary Figure 2). This was not surprising,
255	because published studies have shown an elevated risk of cardiovascular diseases

associated with COVID-19.[12–14,30] However, to our knowledge, our study is the

257	first to have quantified the magnitude of life expectancy shortening in Japan caused by
258	cardiovascular deaths in 2022. The negative change in contributions by respiratory
259	causes from 2021 to 2022 and the consistently negative trend in contributions by
260	neoplastic disorders since 2020 are also of note. In addition to COVID-19-associated
261	conditions, these findings may be attributable to an array of factors including changes in
262	hospital attendance. [18] There is a gap between these findings and the global and
263	regional cause-specific contributions to life expectancy change from 2019–21. Further
264	update on this issue is warranted to evaluate changes in life expectancy change by
265	causes of death. The increase in the contribution of remaining causes of death is mostly
266	explained by the increase in deaths due to senility, which increased by around 20,000 in
267	2021 and 27,000 in 2022. [24]
268	The changes in life span equality during the COVID-19 pandemic were also of
269	note. Our result highlights the undesirable increase in life span equality despite the
270	shortening of life expectancy at birth. This was in line with the substantial negative
271	contribution by the older population to life expectancy changes in the same period,
272	highlighted by the Arriaga decomposition results. These findings add to demographic
273	case studies on the historical relationship between life expectancy and life span equality.
274	[22,23]

275	Our study had some limitations. First, we could not examine the relationship
276	between COVID-19 and other causes of death in detail at the prefectural level, because
277	data on prefectural death count stratified by age and cause of death are not openly
278	accessible. Detailed analysis of prefectural data would have provided insights on
279	geographic heterogeneity, and we hope to explore this in future. Second, we ignored
280	geographic and temporal variation in the ascertainment bias for COVID-19 statistics.
281	We sufficiently met our key focus to be confident about the true mortality burden of
282	COVID-19, but these factors could have biased our analysis of the relationship between
283	prefectural COVID-19 statistics and life expectancy change. Third, we did not consider
284	the fluctuation in the coverage of death registrations in Japan from 2019–22. However,
285	it is unlikely that we missed a large proportion of deaths that would substantially affect
286	our results, because the completeness of death registration is reported to be 90-99% in
287	Japan. [24]
288	In conclusion, our demographic analysis showed the impact of the COVID-19
289	epidemic up to 2022, when the epidemic grew substantially larger. The demographic
290	burden of the pandemic increased more in 2022 than in 2021 or before, but the COVID-
291	19 burden reported by epidemiological surveillance failed to capture this trend. This is
292	probably due to both the shrinking coverage of epidemiological surveillance and the

293	growing impact of	of COVID-19-associated	deaths caused by	complications such as
-----	-------------------	------------------------	------------------	-----------------------

- 294 cardiovascular disorders. We also showed an undesirable increase in life span equality
- due to disproportionately higher mortality among older people. Our study therefore
- provides valuable insights into the mortality impact of the COVID-19 epidemic in Japan,
- which can now only be captured by indirect measures such as demographic analysis in
- the absence of meticulous epidemiological surveillance.

299

300 Acknowledgment

- 301 We thank Melissa Leffler, MBA, of Edanz (https://jp.edanz.com/ac) for editing a draft
- 302 of this manuscript.

303

304 Funding Sources

305	Y.O. received funding from the SECOM Science and	Technology Foundation
505	1.0. received funding from the SECOW Science and	reenhology roundation.

- 306 H.N. received funding from Health and Labour Sciences Research Grants (grant
- 307 numbers 20CA2024, 21HB1002, 21HA2016, and 23HA2005), the Japan Agency for
- 308 Medical Research and Development (grant numbers JP23fk0108612 and
- 309 JP23fk0108685), JSPS KAKENHI (grant numbers 21H03198 and 22K19670), the
- 310 Environment Research and Technology Development Fund (grant number

311	JPMEERF20S11804)	of the Environmental	Restoration and	Conservation A	Agency	of
-----	------------------	----------------------	-----------------	----------------	--------	----

- 312 Japan, Kao Health Science Research, the Daikin GAP Fund of Kyoto University, the
- 313 Japan Science and Technology Agency SICORP program (grant numbers JPMJSC20U3
- and JPMJSC2105), and the RISTEX program for Science, Technology, and Innovation
- 315 Policy (grant number JPMJRS22B4). The funders had no role in the study design, data
- 316 collection and analysis, the decision to publish, or the preparation of the manuscript.
- 317

318 Conflict of interest

319 We declare that we have no conflicts of interest.

320 Ethical approval statement

- 321 Ethical approval was not required because none of the data used in this study included
- any personally identifiable information.

323 Data availability

- 324 We used openly accessible COVID-19 statistics from the website of the Ministry of
- Health, Labour and Welfare, and life tables and related statistics from the website of
- 326 National Institute of Population and Social Security Research. The supplementary files

327 include the datasets used in this study, and also the results of our numerical analyses.

- 328 None of the data used in this study contained personally identifiable information.
- 329

330 References

331	[1]	Bilal U, Hessel P, Perez-Ferrer C, Michael YL, Alfaro T, Tenorio-Mucha J, et al.
332		Life expectancy and mortality in 363 cities of Latin America. Nature Medicine
333		2021 27:3 2021;27:463–70. https://doi.org/10.1038/s41591-020-01214-4.
334	[2]	Wang H, Paulson KR, Pease SA, Watson S, Comfort H, Zheng P, et al.
335		Estimating excess mortality due to the COVID-19 pandemic: a systematic
336		analysis of COVID-19-related mortality, 2020-21. Lancet 2022;399:1513–36.
337		https://doi.org/10.1016/S0140-6736(21)02796-3.
338	[3]	Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S,
339		Wakefield J. The WHO estimates of excess mortality associated with the
340		COVID-19 pandemic. Nature 2022 613:7942 2022;613:130–7.
341		https://doi.org/10.1038/s41586-022-05522-2.
342	[4]	Schumacher AE, Kyu HH, Aali A, Abbafati C, Abbas J, Abbasgholizadeh R, et
343		al. Global age-sex-specific mortality, life expectancy, and population estimates in
344		204 countries and territories and 811 subnational locations, 1950–2021, and the
345		impact of the COVID-19 pandemic: a comprehensive demographic analysis for
346		the Global Burden of Disease Study 2021. The Lancet 2024;0.
347		https://doi.org/10.1016/s0140-6736(24)00476-8.
348	[5]	Schöley J, Aburto JM, Kashnitsky I, Kniffka MS, Zhang L, Jaadla H, et al. Life
349		expectancy changes since COVID-19. Nature Human Behaviour 2022 6:12
350		2022;6:1649-59. https://doi.org/10.1038/s41562-022-01450-3.
351	[6]	Aburto JM, Schöley J, Kashnitsky I, Zhang L, Rahal C, Missov TI, et al.
352		Quantifying impacts of the COVID-19 pandemic through life-expectancy losses:
353		a population-level study of 29 countries. Int J Epidemiol 2022;51:63–74.
354		https://doi.org/10.1093/IJE/DYAB207.
355	[7]	Watson OJ, Barnsley G, Toor J, Hogan AB, Winskill P, Ghani AC. Global
356		impact of the first year of COVID-19 vaccination: a mathematical modelling
357		study. Lancet Infect Dis 2022;22:1293-302. https://doi.org/10.1016/S1473-
358		3099(22)00320-6.

359	[8]	Link-Gelles R, Levy ME, Natarajan K, Reese SE, Naleway AL, Grannis SJ, et al.
360		Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness
361		and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage
362		Periods. JAMA Netw Open 2023;6:e232598-e232598.
363		https://doi.org/10.1001/JAMANETWORKOPEN.2023.2598.
364	[9]	Rossman H, Meir T, Somer J, Shilo S, Gutman R, Ben Arie A, et al. Hospital
365		load and increased COVID-19 related mortality in Israel. Nature
366		Communications 2021 12:1 2021;12:1-7. https://doi.org/10.1038/s41467-021-
367		22214-z.
368	[10]	Hayashi K, Nishiura H. Time-dependent risk of COVID-19 death with
369		overwhelmed health-care capacity in Japan, 2020–2022. BMC Infect Dis
370		2022;22:1-10. https://doi.org/10.1186/S12879-022-07929-8/FIGURES/4.
371	[11]	French G, Hulse M, Nguyen D, Sobotka K, Webster K, Corman J, et al. Impact
372		of Hospital Strain on Excess Deaths During the COVID-19 Pandemic — United
373		States, July 2020–July 2021. MMWR Morb Mortal Wkly Rep 2021;70:1613–6.
374		https://doi.org/10.15585/MMWR.MM7046A5.
375	[12]	Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, et al. Association of
376		COVID-19 With Major Arterial and Venous Thrombotic Diseases: A Population-
377		Wide Cohort Study of 48 Million Adults in England and Wales. Circulation
378		2022;146:892-906. https://doi.org/10.1161/CIRCULATIONAHA.122.060785.
379	[13]	Raisi-Estabragh Z, Cooper J, Salih A, Raman B, Lee AM, Neubauer S, et al.
380		Cardiovascular disease and mortality sequelae of COVID-19 in the UK Biobank.
381		Heart 2023;109:119-26. https://doi.org/10.1136/HEARTJNL-2022-321492.
382	[14]	Lee WE, Park SW, Weinberger DM, Olson D, Simonsen L, Grenfell BT, et al.
383		Direct and indirect mortality impacts of the COVID-19 pandemic in the United
384		States, March 1, 2020 to January 1, 2022. Elife 2023;12.
385		https://doi.org/10.7554/ELIFE.77562.
386	[15]	Kayano T, Sasanami M, Kobayashi T, Ko YK, Otani K, Suzuki M, et al. Number
387		of averted COVID-19 cases and deaths attributable to reduced risk in vaccinated
388		individuals in Japan. Lancet Reg Health West Pac 2022;28.
389		https://doi.org/10.1016/j.lanwpc.2022.100571.
390	[16]	Andrews N, Stowe J, Kirsebom F, Toffa S, Rickeard T, Gallagher E, et al. Covid-
391		19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England
392		Journal of Medicine 2022;386:1532–46.
393		https://doi.org/10.1056/NEJMOA2119451/SUPPL_FILE/NEJMOA2119451_DI
394		SCLOSURES.PDF.

395	[17]	Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J, de Silva TI, et al.
396		SARS-CoV-2 variant biology: immune escape, transmission and fitness. Nature
397		Reviews Microbiology 2023 21:3 2023;21:162-77.
398		https://doi.org/10.1038/s41579-022-00841-7.
399	[18]	Munira MS, Okada Y, Nishiura H. Life-expectancy changes during the COVID-
400		19 pandemic from 2019–2021: estimates from Japan, a country with low
401		pandemic impact. PeerJ 2023;11:e15784.
402		https://doi.org/10.7717/PEERJ.15784/SUPP-4.
403	[19]	Woolf SH, Masters RK, Aron LY. Effect of the covid-19 pandemic in 2020 on
404		life expectancy across populations in the USA and other high income countries:
405		simulations of provisional mortality data. BMJ 2021;373:1343.
406		https://doi.org/10.1136/BMJ.N1343.
407	[20]	Nomura S, Eguchi A, Tanoue Y, Yoneoka D, Kawashima T, Suzuki M, et al.
408		Excess deaths from COVID-19 in Japan and 47 prefectures from January through
409		June 2021. Public Health 2022;203:15-8.
410		https://doi.org/10.1016/J.PUHE.2021.11.023.
411	[21]	Excess and Exiguous Deaths Dashboard in Japan. Total Number of Deaths
412		exdeaths-japan.org 2023. https://exdeaths-japan.org/en/graph/numberof (accessed
413		June 1, 2023).
414	[22]	Aburto JM, Villavicencio F, Basellini U, Kjærgaard S, Vaupel JW. Dynamics of
415		life expectancy and life span equality. Proc Natl Acad Sci U S A 2020;117:5250-
416		9.
417		https://doi.org/10.1073/PNAS.1915884117/SUPPL_FILE/PNAS.1915884117.SA
418		PP.PDF.
419	[23]	Colchero F, Rau R, Jones OR, Barthold JA, Conde DA, Lenart A, et al. The
420		emergence of longevous populations. Proc Natl Acad Sci U S A
421		2016;113:E7681–90.
422		https://doi.org/10.1073/PNAS.1612191113/SUPPL_FILE/PNAS.201612191SI.P
423		DF.
424	[24]	Okada Y, Nishiura H. Supplementary references for open data used in "Changes
425		in life expectancy and life span equality during the COVID-19 epidemic in Japan
426		up to 2022." 2024.
427	[25]	Arriaga EE. Measuring and explaining the change in life expectancies.
428		Demography 1984;21:83-96. https://doi.org/10.2307/2061029/METRICS.
429	[26]	Keyfitz N. Mortality Comparisons; The Male-Female Ratio 1985:54–76.
430		https://doi.org/10.1007/978-1-4757-1879-9_3.

- 431 [27] Aburto JM, Alvarez JA, Villavicencio F, Vaupel JW. The threshold age of the
- 432 lifetable entropy. Demogr Res 2019;41:83–102.
- 433 https://doi.org/10.4054/DEMRES.2019.41.4.
- 434 [28] National Institute of Population and Social Security Research. The Japanese
- 435 Mortality Database | National Institute of Population and Social Security
- 436 Research 2023. https://www.ipss.go.jp/p-toukei/JMD/index-en.asp (accessed
 437 June 1, 2023).
- 438 [29] R Core Team. R: The R Project for Statistical Computing 2023. https://www.r439 project.org/ (accessed June 25, 2023).
- 440 [30] Burn E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, Kostka K, Delmestri A,
- 441 et al. Venous or arterial thrombosis and deaths among COVID-19 cases: a
- 442 European network cohort study. Lancet Infect Dis 2022;22:1142–52.
- 443 https://doi.org/10.1016/S1473-3099(22)00223-7.
- 444
- 445

446 Figure 1. Life expectancy changes from 2019–20, 2020–21, and 2021–22 by

447 prefecture.

- 448 Changes from (A) 2019–20, (B) 2020–21, and (C) 2021–22 are shown. In each panel,
- bars in blue show positive changes, and red bars show negative changes. Prefectures are
- 450 shown in ascending order by life expectancy change in 2021–22.
- 451

452 Figure 2. Correlation between life expectancy changes and COVID-19 burden

- 453 from official statistics.
- 454 Correlation between life expectancy changes and the reported numbers of (A) annual
- 455 COVID-19 cases, (B) person-days in intensive care due to COVID-19, and (C) deaths
- 456 due to COVID-19 are shown. The variables on the x-axis are log-scaled in all panels. In
- 457 each panel, individual prefectures are shown as black triangles for 2020–21 data, or red
- 458 dots for 2021–22 data. The horizontal dashed line corresponds to "no year-on-year life
- 459 expectancy change".
- 460

461 Figure 3. Arriaga decomposition of life expectancy change by major cause of death462 and age group, for the total population of Japan.

- 463 Decomposed contribution by age for (A) 2019–20, (B) 2020–21, (C) 2021–22 are
- 464 shown in each panel. The key to the colors of bars for each major cause are shown in
- the panel below the plots. Bars representing major causes with a positive contribution to
- 466 life expectancy are stacked on the right-hand side, and those making negative
- 467 contributions are stacked on the left-hand side.
- 468

469 Figure 4. The trend in life span equality from 2000 to 2022, for the total population470 of Japan.

- 471 Panel (A) shows the dynamics of life span equality by time from 2000 to 2022. Panel
- (B) shows the same dynamics in relation to life expectancy for the same period, and the
- 473 years corresponding to the red dots are noted within the figure.
- 474
- 475

476 Table 1. Life expectancy change and COVID-19 statistics: summary of linear

477 regression analysis.

478

COVID-19 data (log-scale)	Year	Coefficient (95% CI*)	Intercept (95% CI)
Cases	2020-21	-0.104 (-0.189, -0.018)	-0.655 (-1.086, -0.224)
	2021-22	-0.104 (-0.496, 0.288)	-0.652 (-1.266, -0.037)
Person-days in intensive care	2020-21	-0.082 (-0.144, -0.021)	-0.704 (-1.132, -0.277)
	2021-22	-0.053 (-0.117, 0.011)	-0.879 (-1.353, -0.405)
Death	2020-21	-0.067 (-0.137, -0.002)	-0.789 (-1.464, -0.114)
	2021-22	-0.105 (-0.269, 0.060)	-1.338 (-2.671, -0.057)


479 *CI, confidence interval

480


481


Life expectancy changes (years) by prefecture, Total Population

Iwate Okinawa Kyoto Kumamoto Kochi Miyazaki Kagoshima Fukui Ibaraki Chiba Ishikawa Yamanashi Tochigi Akita Wakayama Yamagata Kanagawa Hiroshima Miyagi Toyama Nara Prefecture Nagano Fukuoka Shizuoka Aichi Shiga Osaka⁻ Saitama Gifu Okayama Shimane Kagawa Saga Tokyo Hokkaido Fukushima Gunma Mie Oita Tokushima Aomori



Life expectancy changes (years) and reported COVID-19 burden by prefecture





Cause of Death

